OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-UpYaël C. Cohen, María-Victoria Mateos Manteca, Enrique M. Ocio et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0